Efficacy and safety of balovaptan for socialisation and communication difficulties in autistic adults in North America and Europe: a phase 3, randomised, placebo- controlled trial

Jeremy Veenstra-VanderWeele, Suma Jacob, Declan Murphy, James McCracken, Janice Smith, Kevin Sanders, Christoph Meyenberg, Thomas Wiese, Gurpreet Deol-Bhullar, Christoph Wandel, Elizabeth Ashford, Evdokia Anagnostou

Research output: Contribution to journalArticlepeer-review

Original languageEnglish
Pages (from-to)199-210
Number of pages12
JournalThe Lancet Psychiatry
Issue number3
Early online date10 Feb 2022
Publication statusPublished - 10 Feb 2022


  • autism
  • balovaptan
  • communication

Cite this